Get the Stockscreener App
33.10
0.21%
0.075
Tema Etf Trust Tema Obesity Cardiometabolic Etf stock is traded at $33.10, with a volume of 3,320.
It is up +0.21% in the last 24 hours and down -0.51% over the past month.
See More
Previous Close:
$33.03
Open:
$32.93
24h Volume:
3,320
Relative Volume:
0.20
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.69%
1M Performance:
-0.51%
6M Performance:
+2.57%
1Y Performance:
+0.00%
1-Day Range:
$32.66
$33.15
1-Week Range:
$32.52
$33.25
52-Week Range:
$26.26
$36.03
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Company Profile
Name
Tema Etf Trust Tema Obesity Cardiometabolic Etf
Sector
Industry
Phone
-
Address
-
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Latest News
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
(HRTS) Proactive Strategies - Stock Traders Daily
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga
Tema Endowment ETF plans to ride Wall Street’s private-asset craze - Pensions & Investments
Stone Ridge 2060 Inflation Protected Longevity Income ETF (LIAU) Chart and Price History 2024 - MarketBeat
An Endowment ETF Plans to Ride Wall Street’s Private-Asset Craze - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Shares Up 0.1% - Defense World
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
HRTS: Generating Alpha In Obesity Treatment (NASDAQ:HRTS) - Seeking Alpha
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside - Seeking Alpha
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Benzinga
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say 'No' - Bloomberg
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Stock Price Down 1.1% - Defense World
Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard
Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg
Spot Ether ETF: a Crypto Game Changer? - Opto RoW
ETFs to Profit from the Weight Loss Drug Boom - Yahoo Finance
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Investing in the diabesity epidemic: a breakthrough moment - Opto RoW
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
Thematic ETF Winners of the Q1 2024 Earnings Season - ETF Trends
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
The Impact of Bitcoin Halving on Investors and ETFs to Explore - The Globe and Mail
A New Horizon: Horizons ETF Management Canada to rebrand as Global X - The Globe and Mail
Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily
'Continued innovation' is key when investing in weight loss trend - Yahoo Finance
Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space - Investor's Business Daily
The Truth HRTSETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet
US ETF launches from 16th to 23rd November, 2023 - ETF Express
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade - MarketWatch
New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - BNN Bloomberg
Be Thankful — It Could Have Been So Much Worse - Bloomberg
Tema Etf Trust Tema Obesity Cardiometabolic Etf Stock (HRTS) Financials Data
There is no financial data for Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.74%
Cap:
|
Volume (24h):